AIMMUNE THERAPEUTICS, INC. (NASDAQ:AIMT) Files An 8-K Submission of Matters to a Vote of Security Holders

AIMMUNE THERAPEUTICS, INC. (NASDAQ:AIMT) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07

Story continues below

Submission of Matters to a Vote of Security Holders.

On May23, 2018, Aimmune Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders voted on four proposals, each of which is described in more detail in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April11, 2018. Only stockholders of record as of the close of business on March29, 2018, the record date for the Annual Meeting, were entitled to vote at the Annual Meeting.As of the record date, 58,024,282 shares of the Company’s common stock were outstanding and entitled to vote at the Annual Meeting. The tabulation of the stockholder votes on each proposal brought before the Annual Meeting is as follows:

Proposal 1. The election of two directors to hold office until the 2021 annual meeting of stockholders or until their respective successor is elected:

Nominee

Votes For

Votes Withheld

Broker Non-Votes

Patrick G. Enright

41,106,361

5,283,848

6,597,942

Kathryn Falberg

41,151,690

5,238,519

6,597,942

Proposal 2. The ratification of the selection, by the audit committee of the board of directors of the Company, of KPMG, LLP, as the independent registered public accounting firm of the Company for the fiscal year ending December31, 2018:

Votes For

VotesAgainst

Abstentions

52,933,731

35,637

18,783

As a routine proposal under applicable rules, no broker non-votes were recorded in connection with this proposal.

Proposal 3. The approval, on a non-binding, advisory basis, of the compensation of the Company’s named executive officers:

Votes For

VotesAgainst

Abstentions

Broker Non-Votes

40,766,992

5,609,210

14,007

6,597,942

Proposal 4. The non-binding advisory vote regarding the frequency of future advisory votes by stockholders on the compensation of the Company’s named executive officers:

1 Year

2 Years

3 Years

Abstentions

Broker Non-Votes

46,352,582

18,293

11,778

7,556

6,597,942


About AIMMUNE THERAPEUTICS, INC. (NASDAQ:AIMT)

Aimmune Therapeutics, Inc., formerly Allergen Research Corporation, is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which is referred to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services. It has initiated Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE), its Phase III registration trial of AR101. AR101 has been granted Fast-Track designation and Breakthrough Therapy designation. For patients in the up-dosing phase of the AR101 treatment regimen, AR101 would be provided in a series of color coded pharmaceutical grade capsules of various dose levels.

An ad to help with our costs